Temasek-backed life sciences investor ClavystBio has co-anchored the $11.6-million Series A funding round of Respiree, a healthtech company focused on AI-powered patient monitoring, according to an announcement.
The round, which was also co-led by diagnostics startups investor We Venture Capital, will help support the expansion of Respiree’s commercial team and US presence, per the announcement.
The latest funding round also included participation from Adaptive Capital Partners, Mayo Clinic’s investment arm through conversion of note securities, and existing backers such as Greenwillow Capital Management, Seeds Capital, and she1K.
Respiree develops AI tools aimed at automating patient monitoring and care pathway management. Its flagship model, trained during the Mayo Clinic Platform_Accelerate program, helps detect early signs of patient deterioration in hospitals.
Founded in Singapore, Respiree’s platform integrates data from electronic health records, wearable sensors, and third-party devices to track disease progression and enable earlier interventions.
The company is seeking FDA clearance for integration of the model into its 1Bio platform. Its proprietary sensors are already FDA-cleared and CE-marked.
“The digitalisation of healthcare offers a powerful opportunity to improve outcomes and efficiency, but without the right tools, it risks overwhelming care systems, especially amid workforce shortages,” said Dr. Gurpreet Singh, founder and CEO of Respiree.
Respiree has operations in the US, Australia, and across Asia-Pacific, with recent pilot collaborations launched in partnership with Roche Diagnostics.
The company plans to enter new markets, including the Gulf Cooperation Council and Thailand.
Anselm Tan, Digital Health & MedTech lead at ClavystBio, said the firm’s investment in Respiree aligns with its strategy to support companies scaling globally from Singapore.
“This further underscores our commitment to accelerating medtech innovations aimed at improving patient outcomes across care settings,” Tan said.
ClavystBio is a life sciences investor and venture builder established by Temasek to accelerate the commercialisation of breakthrough ideas into health impact.
It recently signed an agreement with Singapore’s Agency for Science, Technology, and Research (A*STAR) to co-develop and commercialise medtech innovations in the city-state.
ClavystBio will provide capital, business guidance, and industry networks, while A*STAR will contribute technical expertise and incubate ventures.
